Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Care in RA
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years;
• Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;
• Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).
Locations
Other Locations
Canada
Sir Mortimer B. Davis Jewish General Hospital
RECRUITING
Montreal
Contact Information
Primary
Marie Hudson, MD
marie.hudson@mcgill.ca
514-340-8222
Time Frame
Start Date: 2023-02-01
Estimated Completion Date: 2030-12
Participants
Target number of participants: 75
Treatments
Active_comparator: Sub-study 1 TNFi
TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)
Active_comparator: Sub-study 1 Anti-IL6
Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
Active_comparator: Sub-study 2 Anti-IL6
Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
Active_comparator: Sub-study 2 JAKi
JAKi - tofacitinib (JAK1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (JAK1 inhibitor)
Related Therapeutic Areas
Sponsors
Collaborators: Lady Davis Institute, Montreal General Hospital, McGill University Health Centre/Research Institute of the McGill University Health Centre
Leads: Marie Hudson, MD